Home  >  Research  >  Labs  >  Cardiovascular Science and Diabetes Program  >  MOLECULAR ENDOCRINOLOGY AND PHARMACOLOGY


Endocrinology and Pharmacology are the study of how hormones and pharmaceuticals act in the body respectively. At the molecular and cellular level, the focus is upon the receptors in the cell membranes that bind the hormones and pharmaceuticals, transmitting or blocking specific signals into our cells. The laboratory’s work is currently focused primarily on developing better treatments for kidney disease, cardiovascular disease and cancer.

This group mainly studies the molecular function of G protein-coupled receptors (GPCRs) and their signalling pathways, but is also starting to expand into other target classes such as receptor tyrosine kinases (RTKs), because of their importance in cancer in particular (Ayoub et al., 2013; O’Brien et al., 2018), and the Receptor for Advanced Glycation End-Products (RAGE), especially because of its importance in cardiovascular disease (Pickering et al., 2019).

GPCRs are a family of over 800 different cell surface sensors in the human body. Their function is diverse and, among many more, includes the detection of light (vision) and odorants (smell), as well as the regulation of growth, metabolism, reproduction, immune responses etc. Key GPCRs also have important roles in cancer, such as the chemokine receptors (Watts et al., 2013). Not surprisingly, between a third and a half of all currently available pharmaceuticals modulate GPCR function to mitigate various diseases and conditions.

The major research focus of the group is the study of receptor complexes and their role in receptor function. Receptors interact with a variety of different proteins as well as other receptors, and it is important to understand how the resultant complexes work in terms of signalling and regulation. The aim is to use this knowledge to develop substantially improved pharmaceuticals with fewer side effects.

Professor Kevin Pfleger

Professor Kevin Pfleger

Molecular Endocrinology and Pharmacology

Read more


Biodesign program wins national award for excellence

A program that provides industry engagement opportunities and training in biomedical design thinking, while giving industry access to research talent has won a national award. iPREP Biodesign, administered by The University of Western Australia on behalf of nine universities across the country, has been recognised with the 2024 Australian Council…

Read More

Phase 3 drug trial for rare chronic kidney disease achieves key milestone

Biopharmaceutical company, Dimerix Limited (ASX: DXB, “Dimerix”), which is developing new treatments for types of inflammatory kidney and respiratory diseases, has announced successful interim results of a Phase 3 trial of DMX-200 in patients with the rare disease Focal Segmental Glomerulosclerosis (FSGS) that attacks the kidney’s filtering units. The chronic…

Read More

Federal government supports new treatment to clear blocked arteries

A Western Australian medical research team developing a new treatment for cardiovascular disease has received $2,147,254 in Federal government funding to develop a first-ever drug to clear blocked arteries. The National Health and Medical Research Council (NHMRC) Ideas Grant for innovative research has been awarded to Associate Professor Juliana Hamzah…

Read More